Novo Nordisk A/S - Product Pipeline Review - 2016

1 of 4
Novo Nordisk A/S - Product Pipeline Review - 2016

Summary

‘Novo Nordisk A/S - Product Pipeline Review - 2016’, provides an overview of the Novo Nordisk A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novo Nordisk A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Novo Nordisk A/S
- The report provides overview of Novo Nordisk A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Novo Nordisk A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Novo Nordisk A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Novo Nordisk A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Novo Nordisk A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Novo Nordisk A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Novo Nordisk A/S Snapshot

Novo Nordisk A/S Overview

Key Information

Key Facts

Novo Nordisk A/S - Research and Development Overview

Key Therapeutic Areas

Novo Nordisk A/S - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Novo Nordisk A/S - Pipeline Products Glance

Novo Nordisk A/S - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Novo Nordisk A/S - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Novo Nordisk A/S - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Novo Nordisk A/S - Drug Profiles

(insulin aspart + insulin degludec)

Product Description

Mechanism of Action

R&D Progress

(insulin degludec + liraglutide)

Product Description

Mechanism of Action

R&D Progress

insulin degludec

Product Description

Mechanism of Action

R&D Progress

NN-1218

Product Description

Mechanism of Action

R&D Progress

nonacog beta pegol

Product Description

Mechanism of Action

R&D Progress

NN-9535

Product Description

Mechanism of Action

R&D Progress

somapacitan

Product Description

Mechanism of Action

R&D Progress

turoctocog alfa pegol

Product Description

Mechanism of Action

R&D Progress

liraglutide (recombinant)

Product Description

Mechanism of Action

R&D Progress

liraglutide (recombinant) + NN-8828

Product Description

Mechanism of Action

R&D Progress

NN-9536

Product Description

Mechanism of Action

R&D Progress

NN-9709

Product Description

Mechanism of Action

R&D Progress

OG-217SC

Product Description

Mechanism of Action

R&D Progress

OI-338GT

Product Description

Mechanism of Action

R&D Progress

AM-833

Product Description

Mechanism of Action

R&D Progress

concizumab

Product Description

Mechanism of Action

R&D Progress

G-530L

Product Description

Mechanism of Action

R&D Progress

LAI-287

Product Description

Mechanism of Action

R&D Progress

NN-1406

Product Description

Mechanism of Action

R&D Progress

NN-9747

Product Description

Mechanism of Action

R&D Progress

NN-9748

Product Description

Mechanism of Action

R&D Progress

OI-320GT

Product Description

Mechanism of Action

R&D Progress

Insulin

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides to Agonize NMUR1 and NMUR2 for Obesity and Diabetes

Product Description

Mechanism of Action

R&D Progress

XMet-A

Product Description

Mechanism of Action

R&D Progress

Novo Nordisk A/S - Pipeline Analysis

Novo Nordisk A/S - Pipeline Products by Target

Novo Nordisk A/S - Pipeline Products by Route of Administration

Novo Nordisk A/S - Pipeline Products by Molecule Type

Novo Nordisk A/S - Pipeline Products by Mechanism of Action

Novo Nordisk A/S - Recent Pipeline Updates

Novo Nordisk A/S - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

balaglitazone

coagulation factor XIII A-subunit (recombinant)

LAI-338

liraglutide (recombinant)

NN-1952

NN-1954

NN-1955

NN-1956

NN-1998

NN-7128

NN-7129

NN-8555

NN-8828

NN-9112

NN-9161

NN-9925

NNC126-0083

OG-217GT

OG-987GT

OG-987SC

ragaglitazar

semaglutide

tifenazoxide

vatreptacog alfa (activated)

Novo Nordisk A/S - Company Statement

Novo Nordisk A/S - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Novo Nordisk A/S, Key Information

Novo Nordisk A/S, Key Facts

Novo Nordisk A/S - Pipeline by Indication, 2016

Novo Nordisk A/S - Pipeline by Stage of Development, 2016

Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016

Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016

Novo Nordisk A/S - Partnered Products in Pipeline, 2016

Novo Nordisk A/S - Partnered Products/ Combination Treatment Modalities, 2016

Novo Nordisk A/S - Pre-Registration, 2016

Novo Nordisk A/S - Phase III, 2016

Novo Nordisk A/S - Phase II, 2016

Novo Nordisk A/S - Phase I, 2016

Novo Nordisk A/S - Preclinical, 2016

Novo Nordisk A/S - Pipeline by Target, 2016

Novo Nordisk A/S - Pipeline by Route of Administration, 2016

Novo Nordisk A/S - Pipeline by Molecule Type, 2016

Novo Nordisk A/S - Pipeline Products by Mechanism of Action, 2016

Novo Nordisk A/S - Recent Pipeline Updates, 2016

Novo Nordisk A/S - Discontinued Pipeline Products, 2016

Novo Nordisk A/S, Subsidiaries

List of Figures

Novo Nordisk A/S - Pipeline by Indication, 2016

Novo Nordisk A/S - Pipeline by Stage of Development, 2016

Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016

Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016

Novo Nordisk A/S - Partnered Products in Pipeline, 2016

Novo Nordisk A/S - Pipeline by Top 10 Target, 2016

Novo Nordisk A/S - Pipeline by Route of Administration, 2016

Novo Nordisk A/S - Pipeline by Molecule Type, 2016

Novo Nordisk A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll